{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renin+Angiotensin+Aldosterone+System",
    "query": {
      "condition": "Renin Angiotensin Aldosterone System"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 24,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renin+Angiotensin+Aldosterone+System&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T09:05:45.511Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00961207",
      "title": "Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Microalbuminuria",
        "Macroalbuminuric Diabetic Nephropathy",
        "Diabetes",
        "Proteinuria",
        "Albuminuria"
      ],
      "interventions": [
        {
          "name": "Aliskiren",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cook County Health",
      "sponsor_class": "OTHER_GOV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2009-08",
      "completion_date": "2012-09",
      "has_results": false,
      "last_update_posted_date": "2013-10-28",
      "last_synced_at": "2026-05-22T09:05:45.511Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00961207"
    },
    {
      "nct_id": "NCT00685945",
      "title": "Renin-Angiotensin Aldosterone System and Fibrinolysis Interaction in Humans-Specific Aim 3",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Control (bradykinin)",
          "type": "DRUG"
        },
        {
          "name": "L-NMMA + bradykinin",
          "type": "DRUG"
        },
        {
          "name": "Isosorbide + L-NMMA + bradykinin",
          "type": "DRUG"
        },
        {
          "name": "Sildenafil + L-NMMA + bradykinin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 24,
      "start_date": "2007-12",
      "completion_date": "2009-01",
      "has_results": true,
      "last_update_posted_date": "2013-02-25",
      "last_synced_at": "2026-05-22T09:05:45.511Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00685945"
    },
    {
      "nct_id": "NCT00853827",
      "title": "Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Coronary Artery Disease (CAD)",
        "Coronary Atherosclerosis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Aliskiren",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "35 Years and older"
      },
      "enrollment_count": 613,
      "start_date": "2009-03",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2014-06-03",
      "last_synced_at": "2026-05-22T09:05:45.511Z",
      "location_count": 54,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 48 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00853827"
    },
    {
      "nct_id": "NCT03888066",
      "title": "Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hyperkalemia"
      ],
      "interventions": [
        {
          "name": "Patiromer",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vifor Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1195,
      "start_date": "2019-04-24",
      "completion_date": "2021-09-02",
      "has_results": true,
      "last_update_posted_date": "2023-02-24",
      "last_synced_at": "2026-05-22T09:05:45.511Z",
      "location_count": 133,
      "location_summary": "Alexander City, Alabama • Huntsville, Alabama • Phoenix, Arizona + 110 more",
      "locations": [
        {
          "city": "Alexander City",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03888066"
    },
    {
      "nct_id": "NCT03938389",
      "title": "The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "PreDiabetes",
        "Impaired Glucose Tolerance",
        "Obesity",
        "Blood Pressure"
      ],
      "interventions": [
        {
          "name": "Sacubitril-Valsartan Tab 97-103 MG",
          "type": "DRUG"
        },
        {
          "name": "Valsartan 160mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo Oral Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 90,
      "start_date": "2020-02-25",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2025-08-11",
      "last_synced_at": "2026-05-22T09:05:45.511Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03938389"
    },
    {
      "nct_id": "NCT00907374",
      "title": "Low Dose Versus Aggressive Inhibition of the Renin-Angiotensin-Aldosterone (RAS) to Treat Microalbuminuria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Microalbuminuria"
      ],
      "interventions": [
        {
          "name": "benazepril",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Charles Drew University of Medicine and Science",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 46,
      "start_date": "2005-07",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2012-03-30",
      "last_synced_at": "2026-05-22T09:05:45.511Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00907374"
    },
    {
      "nct_id": "NCT01009944",
      "title": "Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Lisinopril, Atenolol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2007-01",
      "completion_date": "2019-03-19",
      "has_results": false,
      "last_update_posted_date": "2021-04-09",
      "last_synced_at": "2026-05-22T09:05:45.511Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01009944"
    },
    {
      "nct_id": "NCT00141778",
      "title": "Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation (AF)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ramipril",
          "type": "DRUG"
        },
        {
          "name": "Spironolactone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 455,
      "start_date": "2005-04",
      "completion_date": "2010-08",
      "has_results": true,
      "last_update_posted_date": "2013-03-22",
      "last_synced_at": "2026-05-22T09:05:45.511Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00141778"
    },
    {
      "nct_id": "NCT00894387",
      "title": "Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Decompensated Heart Failure",
        "Congestive Heart Failure"
      ],
      "interventions": [
        {
          "name": "Aliskiren",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1639,
      "start_date": "2009-05",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2013-11-07",
      "last_synced_at": "2026-05-22T09:05:45.511Z",
      "location_count": 37,
      "location_summary": "Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 29 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Sylmar",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00894387"
    },
    {
      "nct_id": "NCT02431936",
      "title": "Effectiveness of Prazosin on the Urinary Sodium Excretion Response to Mental Stress",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypertension",
        "Stress, Psychological",
        "Blood Pressure"
      ],
      "interventions": [
        {
          "name": "Prazosin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Augusta University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 50,
      "start_date": "2015-04",
      "completion_date": "2019-04-16",
      "has_results": false,
      "last_update_posted_date": "2019-06-20",
      "last_synced_at": "2026-05-22T09:05:45.511Z",
      "location_count": 1,
      "location_summary": "Augusta, Georgia",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02431936"
    }
  ]
}